SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...

As of Monday, January 05, SAB Biotherapeutics, Inc.’s SABS share price has dipped by 5.57%, which has investors questioning if this is right time to buy.

The Staff Accounting Bulletin (SAB) 121 rule was introduced by the SEC in March 2022 as part of its efforts to regulate cryptocurrency custody. It required financial institutions to list any crypto ...

Controversial Securities and Exchange Commission accounting guidance known as SAB 121 has been rescinded. SAB 121 has been viewed as a significant obstacle preventing banks from providing custody ...

Preston Pysh explains how the rescission of SAB 121 could permanently entrench Bitcoin into the financial system, surpassing the importance of a Strategic Bitcoin Reserve. In the rapidly evolving ...

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...

Issued on March 31, 2022, SAB 121 required public companies holding crypto on behalf of their customers to record customer-held crypto assets on their balance sheets as both an asset and a ...

MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...

SAB Biotherapeutics is hoping to continue work on its COVID-19 antibody treatment after the National Institutes of Health (NIH) shut down a funded phase 3 clinical trial when the omicron wave slowed ...